SAFC Wins Commercial Licensing of CHOZN Platform in Asia

05.06.2013 -

Sigma-Aldrich today announced that SAFC Commercial, its custom manufacturing services business unit, has won commercial sales and licensing contracts with two leading Asian biopharmaceutical companies for the purchase of CHOZN, their off-the-shelf cell line production platform.

The CHOZN Platform consists of the CHOZN GS-/- CHO cell line and an optimized set of cGMP-produced, chemically defined (CD) media and feeds designed specifically for the cell line to maximize the production of monoclonal antibodies and other r-proteins.